Matthias M Engelen, Johan Vandesande, Johan De Bent, Christine Van Laer, Veerle Labarque, Marc Jacquemin, Kathelijne Peerlinck, Cedric Hermans, Peter Verhamme, Thomas Vanassche
BACKGROUND: Emicizumab is approved to prevent bleeding in patients with congenital haemophilia A with or without inhibitors. However, no randomized trials addressed the efficacy of emicizumab in acquired haemophilia A (AHA). AIMS: To report the clinical and biochemical response of emicizumab in AHA. METHODS: This single-centre retrospective study included seven adults with AHA between November 2020 and May 2022. We collected patient characteristics, laboratory coagulation parameters, the use of haemostatic agents, bleeds and thrombotic events...
June 5, 2023: Haemophilia: the Official Journal of the World Federation of Hemophilia